ERCC1 Mrna Levels and Survival of Advanced Gastric Cancer Patients Treated with a Modified FOLFOX Regimen

J Wei,Z Zou,X Qian,Y Ding,L Xie,J,Y Zhao,J Feng,Y Ling,Y Liu,L Yu,R Rosell,B Liu
DOI: https://doi.org/10.1038/sj.bjc.6604317
IF: 9.075
2008-01-01
British Journal of Cancer
Abstract:Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 6.2 months; P < 0.0001). Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months; P = 0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months (P < 0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (P < 0.0001). In patients with high mRNA levels of ERCC1, alternative chemotherapy regimens should be considered.
What problem does this paper attempt to address?